Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Cancers 2011, 3(3), 3506-3524; doi:10.3390/cancers3033506
Review

An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC)

1
 and 1,2,*
Received: 9 August 2011; in revised form: 30 August 2011 / Accepted: 5 September 2011 / Published: 13 September 2011
(This article belongs to the Special Issue Cancer Diagnosis and Targeted Therapy)
View Full-Text   |   Download PDF [251 KB, uploaded 13 September 2011]
Abstract: Recent advances in the treatment of non-small cell lung cancer (NSCLC) have led to improvements in patient survival and quality of life. It is unclear whether molecular abnormalities associated with NSCLC cell survival, growth and proliferation are useful in predicting treatment benefit. We conducted a systematic review to establish which biomarkers contribute meaningfully to the management of NSCLC. A team of researchers searched PubMed and conference proceedings (ASCO, ESMO, IASLC, USCAP) using MESH terms for NSCLC and randomized trials (RCT), plus keywords for variables of interest. Evidence from multiple RCTs confirmed that histologic subtype is prognostic for survival and predictive of treatment efficacy and/or toxicity in NSCLC. Likewise, activating mutations of the epidermal growth factor receptor (EGFR) are associated with benefit from EGFR tyrosine kinase inhibitors in patients with advanced non-squamous NSCLC and should be assessed routinely. No biomarkers to date reliably predict response to anti-Vascular Endothelial Growth Factor (VEGF) therapies. There are inconsistent data on the role of ERCC1, BRCA, Beta tubulin III, RRM1, K-RAS, or TP-53 in treatment decisions. These tests should not be routinely used in selecting treatment at this time, whereas EML4/ALK translocations predict responses to specific targeted agents, the optimal assessment of this molecular abnormality has yet to be established. Personalized care of patients with NSCLC based on biomarkers is increasingly important to both clinical practice and research.
Keywords: Non-small-cell lung cancer; targeted therapy; epidermal growth factor receptor; tyrosine kinase inhibitor; molecular marker; biomarker Non-small-cell lung cancer; targeted therapy; epidermal growth factor receptor; tyrosine kinase inhibitor; molecular marker; biomarker
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Quinton, C.; Ellis, P.M. An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC). Cancers 2011, 3, 3506-3524.

AMA Style

Quinton C, Ellis PM. An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC). Cancers. 2011; 3(3):3506-3524.

Chicago/Turabian Style

Quinton, Cindy; Ellis, Peter M. 2011. "An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC)." Cancers 3, no. 3: 3506-3524.



Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert